143 related articles for article (PubMed ID: 1620660)
1. Peripheral factors in the mediation of cholecystokinin-induced satiety as assessed by comparative potencies of cholecystokinin antagonists.
Murphy RB; Smith GP; Schneider LH; Gibbs J
Peptides; 1992; 13(1):77-81. PubMed ID: 1620660
[TBL] [Abstract][Full Text] [Related]
2. Properties of receptors for gastrin and CCK on gastric smooth muscle cells.
Menozzi D; Gardner JD; Jensen RT; Maton PN
Am J Physiol; 1989 Jul; 257(1 Pt 1):G73-9. PubMed ID: 2473654
[TBL] [Abstract][Full Text] [Related]
3. The effect of centrally administered CCK-receptor antagonists on food intake in rats.
Corp ES; Curcio M; Gibbs J; Smith GP
Physiol Behav; 1997 Jun; 61(6):823-7. PubMed ID: 9177553
[TBL] [Abstract][Full Text] [Related]
4. Studies of three non-peptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea-pig ileum.
D'Amato M; Stamford IF; Bennett A
Br J Pharmacol; 1991 Feb; 102(2):391-5. PubMed ID: 2015421
[TBL] [Abstract][Full Text] [Related]
5. Different peripheral and central antagonistic activity of new glutaramic acid derivatives on satiety induced by cholecystokinin in rats.
Makovec F; Bani M; Chistè R; Revel L; Rovati LC; Setnikar I
Regul Pept; 1986 Dec; 16(3-4):281-90. PubMed ID: 3562900
[TBL] [Abstract][Full Text] [Related]
6. Postponement of satiety by blockade of brain cholecystokinin (CCK-B) receptors.
Dourish CT; Rycroft W; Iversen SD
Science; 1989 Sep; 245(4925):1509-11. PubMed ID: 2781294
[TBL] [Abstract][Full Text] [Related]
7. Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin-stimulated beta-endorphin secretion from the rat pituitary.
Millington WR; Mueller GP; Lavigne GJ
J Pharmacol Exp Ther; 1992 May; 261(2):454-61. PubMed ID: 1578360
[TBL] [Abstract][Full Text] [Related]
8. [Effect of cholecystokinin and its antagonists lorglumide, devazepide, and L-365,260 on gastrointestinal motility in rats].
Wang SX
Zhongguo Yao Li Xue Bao; 1993 Sep; 14(5):443-6. PubMed ID: 8010038
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological examination of cholecystokinin (CCK-8)-induced contractile activity in the rat isolated pylorus.
Murphy RB; Smith GP; Gibbs J
Peptides; 1987; 8(1):127-34. PubMed ID: 3033618
[TBL] [Abstract][Full Text] [Related]
10. Synthetic CCK8 analogs with antagonist activity on pancreatic receptors: in vivo study in the rat, compared to non-peptidic antagonists.
Nagain C; Galas MC; Lignon MF; Rodriguez M; Martinez J; Rozé C
Pancreas; 1991 May; 6(3):275-81. PubMed ID: 1713671
[TBL] [Abstract][Full Text] [Related]
11. Proglumide fails to increase food intake after an ingested preload.
Schneider LH; Gibbs J; Smith GP
Peptides; 1986; 7(1):135-40. PubMed ID: 3714531
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin-A receptor mediation of food intake in cats.
Bado A; Durieux C; Moizo L; Roques BP; Lewin MJ
Am J Physiol; 1991 Apr; 260(4 Pt 2):R693-7. PubMed ID: 2012242
[TBL] [Abstract][Full Text] [Related]
13. Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder.
Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
Br J Pharmacol; 1992 May; 106(1):61-6. PubMed ID: 1504732
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a new CCK antagonist, L364,718: in vitro and in vivo studies.
Louie DS; Liang JP; Owyang C
Am J Physiol; 1988 Sep; 255(3 Pt 1):G261-6. PubMed ID: 2458681
[TBL] [Abstract][Full Text] [Related]
15. Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze.
Vasar E; Lang A; Harro J; Bourin M; Bradwejn J
Neuropharmacology; 1994 Jun; 33(6):729-35. PubMed ID: 7936110
[TBL] [Abstract][Full Text] [Related]
16. Role of pylorus in mediating cholecystokinin-stimulated satiety in the Zucker rat.
Berk T; Crochelt RF; Peikin SR
Dig Dis Sci; 1986 May; 31(5):502-5. PubMed ID: 3698766
[TBL] [Abstract][Full Text] [Related]
17. Effect of two new cholecystokinin antagonists on gallbladder emptying in opossums.
Hanyu N; Dodds WJ; Layman RD; Hogan WJ; Colton DG
Am J Physiol; 1991 Feb; 260(2 Pt 1):G258-64. PubMed ID: 1996645
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of satiety by a cholecystokinin antagonist is independent of gastric emptying.
Collins SM; Weingarten HP
Peptides; 1984; 5(3):481-4. PubMed ID: 6089141
[TBL] [Abstract][Full Text] [Related]
19. A new simple mouse model for the in vivo evaluation of cholecystokinin (CCK) antagonists: comparative potencies and durations of action of nonpeptide antagonists.
Lotti VJ; Cerino DJ; Kling PJ; Change RS
Life Sci; 1986 Nov; 39(18):1631-8. PubMed ID: 3773639
[TBL] [Abstract][Full Text] [Related]
20. Potent and sustained satiety actions of a cholecystokinin octapeptide analogue.
Moran TH; Sawyer TK; Seeb DH; Ameglio PJ; Lombard MA; McHugh PR
Am J Clin Nutr; 1992 Jan; 55(1 Suppl):286S-290S. PubMed ID: 1728841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
